Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 October 2023 | Story Michelle Nöthling | Photo iStock
Commemorating World Mental Health Month 2023
The mental health of university students is of growing global concern.

One of the largest student mental health surveys in the world – initiated by Universities South Africa (USAf) in 2020 – found that up to 20% of university students in South Africa need mental health support. The research results also show that up to 77% of students with mental health disorders are not getting help. Contributing reasons include reluctance to seek help due to lingering stigma surrounding mental health, but also limited access. With growing demand and limited capacity, one-on-one therapy does not seem to be a sustainable solution. Some of the recommendations that stem from the report are to introduce a range of digitally based self-help interventions, to provide psychoeducation about when to access help, and to offer peer-to-peer support. This is precisely what the University of the Free State (UFS) Department of Student Counselling and Development (SCD) is now implementing. 

Coinciding with World Mental Health Awareness Month, SCD’s Road Map embodies a paradigm shift in student mental health support. “We want to capacitate students on their mental health journey. Following the Road Map, our students are now able to be active agents in their mental well-being,” says Dr Munita Dunn-Coetzee, SCD Director.

What exactly is this Road Map?

The SCD Road Map guides students to multiple sources of support. On the SCD website, students can delve into a wealth of self-help guides and toolkits that range from academic, emotional, and social well-being to personal challenges and psychological distress. In a commitment to expand the SCD reach beyond one-on-one sessions, the department is offering both in-person and online workshops and development programmes that can be accessed through Blackboard. Additionally, podcasts have been integrated into the SCD offerings to accommodate students' varying schedules and data constraints.

SCD has also partnered with the South African Depression and Anxiety Group (SADAG) to provide a 24/7 toll-free UFS Student Careline. The Careline can be reached in three ways: by calling 0800 00 6363, SMSing 43302, or emailing helpline@sadag.org. In a crisis, help is immediately activated, and assistance is sent to the student.

Another exciting aspect of SCD's Road Map¬ – which further integrates recommendations from the research report – is the shift from individual-centric interventions to group-based support. “We want to expand beyond individual therapy,” Dr Dunn-Coetzee says. “Although one-on-one therapy has an important place in mental health support, we are currently expanding to offer various support groups.” Through these circles of support, SCD aims to foster a culture of mutual learning, peer-to-peer connection, and collective well-being.

The Road Map therefore enables SCD to pivot toward a capacitating approach, equipping students to navigate their mental health journey in a truly collaborative model.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept